On September 10, WUXI XDC fell 3.29% in regular trading, trading at 72.0 HKD/share, with turnover of approximately 190 million HKD.

On the news front, WuXi AppTec and its affiliates recently sold approximately 53.524 million shares of WUXI XDC via block trades at an average price of 73.23 HKD per share, involving total proceeds of approximately 3.92 billion HKD. The disposal reduced WuXi AppTec's stake from 18.36% to 14.14%, and is expected to generate pre-tax investment gains of approximately 3.143 billion RMB, exceeding 10% of the parent's audited net profit for the prior fiscal year. The concentrated selling by the major shareholder created notable short-term overhang pressure on the stock price.

At the sector level, the Life Sciences Tools and Services industry broadly weakened, with GenScript Biotech down 4.16%, WuXi Biologics down 3.15%, and WuXi AppTec down 0.78%. Meanwhile, international asset manager Schroders PLC marginally increased its position to 5.03%, partially offsetting negative sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)